Thomas Jervis salutes the landmark product liability ruling in Boston Scientific
The Court of Justice of the European Union recently published its long awaited decision in Boston Scientific Medizintechnik v AOK Sachsen-Anhalt C503/13 and C504/13. This decision has important ramifications for practitioners in the field of product liability who deal with the EC Product Liability Directive 85/374/EEC (the directive) and the Consumer Protection Act 1987 (CPA 1987).
Boston Scientific suggests that a problem product may be “defective” without having to show that the product is defective in each individual case.
Background
The directive was adopted in 1985 and was implemented into UK law by the CPA 1987. This came in the wake of the Thalidomide scandal, and was a move across the EU to establish a harmonised regime to mediate between the interests of business to make profit and innovate, versus an accessible recourse for injured consumers.
Recital 2 of the directive discusses liability without fault on the part of the producer being “the sole means of adequately solving the problem, peculiar to
.tmb-mov69x69.jpg?sfvrsn=77dbbdb7_1)
.tmb-mov69x69.jpg?sfvrsn=b3bea7f_1)
